^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
GNR-051
i
Other names: GNR-051, GNR 051, GNR051
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Generium
Drug class:
PD1 inhibitor
Related drugs:
9ms
A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies (clinicaltrials.gov)
P1, N=48, Active, not recruiting, AO GENERIUM | Trial completion date: Jun 2024 --> Jan 2025
Trial completion date • Metastases
|
GNR-051
over1year
A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies (clinicaltrials.gov)
P1, N=48, Active, not recruiting, AO GENERIUM | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2024 --> Nov 2022
Enrollment closed • Trial primary completion date • Metastases
|
PD-1 (Programmed cell death 1)
|
GNR-051
3years
A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies (clinicaltrials.gov)
P1, N=48, Recruiting, AO GENERIUM | Trial completion date: Nov 2024 --> Jun 2024 | Trial primary completion date: Nov 2024 --> Apr 2024
Clinical • Trial completion date • Trial primary completion date
|
PD-1 (Programmed cell death 1)
|
GNR-051
Share via
